SLC5A2 and hepatocellular carcinoma: Preliminary evidence suggests positive effects of another class of antidiabetic agents, sodium-glucose cotransporter 2 inhibitors, on the mechanisms leading to the development of hepatocellular carcinoma (HCC) [26].